ACE Inhibitors and Angiotensin Receptor Blockers for the Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus

被引：0
作者：
Poulter, Neil [1 ]
机构：
[1] Imperial Coll London, Imperial Clin Trials Unit ICTU, Prevent Cardiovasc Med, London, England
来源：
CARDIOLOGY AND THERAPY | 2025年
关键词：
Angiotensin-converting enzyme inhibitors; Angiotensin receptor blockers; Cardiovascular outcomes; Hypertension; Randomised controlled trials; All-cause mortality; Guidelines; CONVERTING-ENZYME-INHIBITORS; HIGH-RISK; HYPERTENSIVE PATIENTS; DIABETES-MELLITUS; BLOOD-PRESSURE; MORTALITY; EVENTS; TRIAL; TELMISARTAN; METAANALYSIS;
D O I：
10.1007/s40119-025-00399-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：117 / 121
页数：5
相关论文
共 32 条
  • [1] Baker WL, 2009, ANN INTERN MED, V151, P861, DOI [10.7326/0000605-200912150-00162, 10.7326/0003-4819-151-12-200912150-00162]
  • [2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [3] Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus AMeta-analysis
    Cheng, Jun
    Zhang, Wen
    Zhang, Xiaohui
    Han, Fei
    Li, Xiayu
    He, Xuelin
    Li, Qun
    Chen, Jianghua
    [J]. JAMA INTERNAL MEDICINE, 2014, 174 (05) : 773 - 785
  • [4] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [5] 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
    Cosentino, Francesco
    Grant, Peter J.
    Aboyans, Victor
    Bailey, Clifford J.
    Ceriello, Antonio
    Delgado, Victoria
    Federici, Massimo
    Filippatos, Gerasimos
    Grobbee, Diederick E.
    Hansen, Tina Birgitte
    Huikuri, Heikki, V
    Johansson, Isabelle
    Juni, Peter
    Lettino, Maddalena
    Marx, Nikolaus
    Mellbin, Linda G.
    Ostgren, Carl J.
    Rocca, Bianca
    Roffi, Marco
    Sattar, Naveed
    Seferovic, Petar M.
    Sousa-Uva, Miguel
    Valensi, Paul
    Wheeler, David C.
    Piepoli, Massimo Francesco
    Birkeland, Kare, I
    Adamopoulos, Stamatis
    Ajjan, Ramzi
    Avogaro, Angelo
    Baigent, Colin
    Brodmann, Marianne
    Bueno, Hector
    Ceconi, Claudio
    Chioncel, Ovidiu
    Coats, Andrew
    Collet, Jean-Philippe
    Collins, Peter
    Cosyns, Bernard
    Di Mario, Carlo
    Fisher, Miles
    Fitzsimons, Donna
    Halvorsen, Sigrun
    Hansen, Dominique
    Hoes, Arno
    Holt, Richard I. G.
    Home, Philip
    Katus, Hugo A.
    Khunti, Kamlesh
    Komajda, Michel
    Lambrinou, Ekaterini
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (02) : 255 - 323
  • [6] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [7] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial
    Dahlöf, B
    Sever, PS
    Poulter, NR
    Wedel, H
    Beevers, DG
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    [J]. LANCET, 2005, 366 (9489) : 895 - 906
  • [8] Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981
  • [9] Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
    Haller, Hermann
    Ito, Sadayoshi
    Izzo, Joseph L., Jr.
    Januszewicz, Andrzej
    Katayama, Shigehiro
    Menne, Jan
    Mimran, Albert
    Rabelink, Ton J.
    Ritz, Eberhard
    Ruilope, Luis M.
    Rump, Lars C.
    Viberti, Giancarlo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (10) : 907 - 917
  • [10] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial
    Hansson, L
    Lindholm, LH
    Niskanen, L
    Lanke, J
    Hedner, T
    Niklason, A
    Luomanmäki, K
    Dahlöf, B
    de Faire, U
    Mörlin, C
    Karlberg, BE
    Wester, PO
    Björck, JE
    [J]. LANCET, 1999, 353 (9153) : 611 - 616
1234